Article Sidebar
Views PDF: 98
VALUE OF LDH TEST ON COVID-19 PATIENTS AT CAN THO GENERAL HOSPITAL IN 2020-2021
Main Article Content
Abstract
Background: COVID-19 is a global problem. LDH testing is of interest in differentiating severe COVID-19 patients. Objectives: 1. To determine the average of LDH levels in some severe illness and death in COVID-19 patients; 2. To determine the sensitivity and specificity of the LDH test in predicting some severe illness and death in COVID-19 patients. Materials and method: A cross-sectional descriptive study performed on 120 COVID-19 patients from June 2020 to October 2021. Result: The mean LDH concentration in the group of patients with non-severe and severe COVID-19 was 266 ± 118.5U/L, 384 ± 147.4U/L (p<0.001), in the group of patients not admitted to the ICU. and had an ICU admission was 301 ± 125.6U/L and 415 ± 152.8U/L (p<0.001), in COVID-19 patients without ARDS and with an ARDS was 311 ± 131.9U/L and 432 ± 149.2U/L (p<0.001), in the group of non-fatal and fatal patients was 311 ± 135U/L and 421 ± 147.6U/L (p<0.001). LDH test has sensitivity and specificity was 78.7% and 61.3%, respectively; 69.1% and 67.7%; 73.8% and 67.9%; 71.7% and 64.9% in predicting severe COVID-19 patients, ICU admission, ARDS, and death. Conclusions: LDH concentration are increased in patients with severe, with ICU, with ARDS and die. LDH test has good value in predicting severe COVID-19 patients, ICU, ARDS and death.
Article Details
Keywords
LDH test, COVID-19
References
2. Aloisio, E., Pasqualetti, S., & Panteghini, M. (2021), “Linking lactate dehydrogenase to the severity of COVID-19 cannot ignore the employed methodology”, The American journal of emergency medicine, 45, pp.652-653.
3. Brandon MH. et al. (2020), “Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis”, American Journal of Emergency Medicine, 38, pp.1722-1726.
4. Chen Z et al. (2020), “Laboratory markers associated with COVID-19 progression in patients with or without comorbidity: A retrospective study”, J Clin Lab Anal, 35(1).
5. Dong X, Sun L, Li Y (2020), “Prognostic value of lactate dehydrogenase for in-hospital mortality in severe and critically ill patients with COVID-19”, Int J Med Sci 2020; 17(14), pp.2225-2231.
6. Figueira Gonçalves JM (2020), “Biomarkers of acute respiratory distress syndrome in adults hospitalised for severe SARS-CoV-2 infection in Tenerife Island, Spain”, BMC Res Notes, 13(1), 555.
7. Geng et al. (2021), “Risk factors for developing severe COVID-19 in China: an analysis of disease surveillance data”, Infectious Diseases of Poverty, 2021, pp.10- 48.
8. Huang C, Wang Y, Li X, et al. (2020), “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”, Lancet, 395(10223), pp.497-506.
9. ISARIC Clinical Characterisation Group (2020). “COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study”, medRxiv: the preprint server for health sciences, 20219519.
10. Kishan D. et al. (2021), “Erum ferritin, serum LDH and d-dimer in correlation with the outcome in Covid-19”, International Journal of Medical Research & Review, 9(1), pp.46-53.
11. Scott Gutovitz et al. (2021), “Clinical Characteristics and Laboratory Biomarkers for Patients with Suspected COVID-19 Infection Within HCA Healthcare”, HCA Healthcare Journal, 2(8).
12. Serin I. et al. (2020), “A new parameter in COVID-19 pandemic: initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality”, Journal of Infection and Public Health, 13, pp.1664-1670.
13. Shi J et al. (2020), “Lactate dehydrogenase and susceptibility to deterioration of mild COVID19 patients: a multicenter nested case-control study”, BMC Med, 18(1), pp.168.